Product information and disease descriptionProduct descriptionProduct information
Special populations
12 evidence topics · 7 sources
Phase 3 trial population: age, cardiovascular, urinary, ocular, and pregnancy criteria
“The targeted study population is adults (≥18 years old, no upper age limit) with OSA of any severity defined as an AHI4>5 events/h (hypopneas scored when associated with 4% desaturation) with ≤25% central or mixed apneas (as proportion of total apneas and hypopneas), and PLM arousal index ≤15 events/h on the screening PSG.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Potential participants with clinically significant or medically uncontrolled cardiovascular disease such as unstable atrial fibrillation, untreated or unstable coronary artery disease, heart failure, cerebrovascular events and resting heart rate >100 beats per min or blood pressure greater than 145/90 mmHg were excluded.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Current bothersome symptoms of bladder outlet obstruction including difficulty initiating or maintaining urinary flow, straining, or sensation of incomplete bladder emptying” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Narrow angle glaucoma” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Women who are pregnant or nursing” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Older men: age limits in the earlier trials because of urinary risk
“The trials reported above excluded male patients >65 due to concerns for higher risk of urinary problems with ato-oxy or AD109 in the older male population. Women over 65 years of age were allowed in the trial without any reported safety concerns.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Subgroups by sex, weight class, and baseline severity in SynAIRgy
“In supportive analyses, AD109 improved AHI across diverse subgroups, such as those defined by sex, weight class, and baseline OSA severity (mild, moderate, and severe), supporting the generalizability of study findings to a broad spectrum of patients with OSA.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Reduced CYP2D6 activity: proposed contribution to variability in tolerability
“Tolerability may also have been influenced by interindividual variability in atomoxetine metabolism related to cytochrome P450 2D6 (CYP2D6) status. Individuals with reduced CYP2D6 activity may have higher systemic exposure to atomoxetine, which could contribute to variability in adverse events such as insomnia as well as in heart rate and blood pressure responses.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote